Exact Therapeutics AS - Asset Resilience Ratio

Latest as of December 2024: 64.97%

Exact Therapeutics AS (EXTX) has an Asset Resilience Ratio of 64.97% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EXTX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Nkr99.54 Million

≈ $10.47 Million USD Cash + Short-term Investments

Total Assets

Nkr153.20 Million

≈ $16.12 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Exact Therapeutics AS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see EXTX total assets.

Liquid Assets Composition Over Time

This chart breaks down Exact Therapeutics AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Exact Therapeutics AS for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr99.54 Million	64.97%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr99.54 Million	64.97%

Asset Resilience Insights

Very High Liquidity: Exact Therapeutics AS maintains exceptional liquid asset reserves at 64.97% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Exact Therapeutics AS Industry Peers by Asset Resilience Ratio

Compare Exact Therapeutics AS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	2.58%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Kailera Therapeutics, Inc. Common Stock NASDAQ:KLRA	Biotechnology	64.92%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	78.22%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%

Annual Asset Resilience Ratio for Exact Therapeutics AS (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Exact Therapeutics AS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	64.97%	Nkr99.54 Million ≈ $10.47 Million	Nkr153.20 Million ≈ $16.12 Million	-10.75pp
2023-12-31	75.72%	Nkr46.43 Million ≈ $4.89 Million	Nkr61.32 Million ≈ $6.45 Million	-8.38pp
2022-12-31	84.10%	Nkr69.39 Million ≈ $7.30 Million	Nkr82.51 Million ≈ $8.68 Million	-4.05pp
2021-12-31	88.15%	Nkr103.69 Million ≈ $10.91 Million	Nkr117.63 Million ≈ $12.38 Million	-5.50pp
2020-12-31	93.65%	Nkr159.42 Million ≈ $16.78 Million	Nkr170.23 Million ≈ $17.91 Million	+7.22pp
2019-12-31	86.43%	Nkr45.03 Million ≈ $4.74 Million	Nkr52.10 Million ≈ $5.48 Million	-6.35pp
2018-12-31	92.78%	Nkr58.67 Million ≈ $6.17 Million	Nkr63.23 Million ≈ $6.65 Million	+17.12pp
2017-12-31	75.66%	Nkr15.15 Million ≈ $1.59 Million	Nkr20.02 Million ≈ $2.11 Million	--

pp = percentage points

About Exact Therapeutics AS

OL:EXTX Norway Biotechnology

Market Cap

$4.69 Million

Nkr44.60 Million NOK

Market Cap Rank

#28793 Global

#259 in Norway

Share Price

Nkr0.71

Change (1 day)

-11.88%

52-Week Range

Nkr0.61 - Nkr2.70

All Time High

Nkr40.90